1,120 results match your criteria: "France (A.H.); Hospital Clinic de Barcelona[Affiliation]"
Circ Heart Fail
January 2025
Assistance Publique Hopitaux de Paris (APHP), Pitié-Salpêtrière Hospital, Institute of Cardiology and Institute for Cardiometabolism and Nutrition, Paris, France (A.H., M.L., P. Charron, E.G.).
Alzheimers Dement (Amst)
January 2025
Introduction: Studies have shown that blood biomarkers can differentiate dementia disorders. However, the diagnosis of dementia still relies primarily on cerebrospinal fluid and imaging modalities. The new disease-modifying treatments call for more widely applicable biomarkers.
View Article and Find Full Text PDFOrthop J Sports Med
January 2025
Clinique du sport, Paris, Île-de-France, France.
Background: While there are several scales for measuring patients' outcomes after chronic ankle instability (CAI) surgery, a study comparing the predictive ability of these scores with regard to return to sports (RTS) at the preinjury level is lacking.
Purpose/hypothesis: The purpose of this study was to compare the Ankle Ligament Reconstruction-Return to Sport After Injury (ALR-RSI), American Orthopaedic Foot and Ankle Society (AOFAS), and Karlsson scores in predicting 2-year RTS outcomes after arthroscopic treatment of CAI. It was hypothesized that ALR-RSI would be superior in predicting 2-year RTS outcomes after CAI surgery and that a quantifiable increase in this score would significantly improve RTS outcomes.
J Clin Pharmacol
January 2025
Bayer HealthCare SAS, Lille, France, on behalf of:, Model-Informed Drug Development, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Famotidine, a H-receptor antagonist, is commonly used to treat heartburn and gastroesophageal reflux disease during pregnancy. However, information on the pharmacokinetics (PK) of famotidine in pregnant patients is limited since pregnant patients are usually excluded from clinical trials. This study aimed to develop and evaluate a physiologically based pharmacokinetic (PBPK) model for famotidine in non-pregnant and pregnant populations, and to combine it with a pharmacodynamic (PD) model to predict the effect of famotidine on intragastric pH.
View Article and Find Full Text PDFNat Med
January 2025
Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; and Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia.
Neoadjuvant immunotherapies have shown antitumor activity in melanoma. Substudy 02C of the global, rolling-arm, phase 1/2, adaptive-design KEYMAKER-U02 trial is evaluating neoadjuvant pembrolizumab (anti-PD-1) alone or in combination, followed by adjuvant pembrolizumab, for stage IIIB-D melanoma. Here we report results from the first three arms: pembrolizumab plus vibostolimab (anti-TIGIT), pembrolizumab plus gebasaxturev (coxsackievirus A21) and pembrolizumab monotherapy.
View Article and Find Full Text PDFBackground: The co-occurrence of anterior cruciate ligament (ACL) rupture with medial collateral ligament (MCL) rupture is a compound injury that can be associated with meniscal tears.
Purpose: To report the characteristics of meniscal tears in knees with isolated ACL versus combined ACL and MCL injuries, analyzing their frequency, distribution by site, and lesion type.
Study Design: Cross-sectional study; Level of evidence, 3.
Nat Commun
December 2024
Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10-15% of muscle-invasive and metastatic urothelial cancer (MIBC/mUC) are FGFR3-mutant. Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.
View Article and Find Full Text PDFSchizophrenia (Heidelb)
December 2024
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Previous studies have suggested that choroid plexus (ChP) enlargement occurs in individuals with schizophrenia-spectrum disorders (SSD) and is associated with peripheral inflammation. However, it is unclear whether such an enlargement delineates a biologically defined subgroup of SSD. Moreover, it remains elusive how ChP is linked to brain regions associated with peripheral inflammation in SSD.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
December 2024
Department of Materials Science WW4-LKO, Friedrich-Alexander-University of Erlangen-Nuremberg, Martensstrasse 7, 91058, Erlangen, Germany.
The use of metal single atoms (SAs) as co-catalysts on semiconductors has emerged as a promising technology to enhance their photocatalytic hydrogen production performance. In this study, we describe the deposition of very low amounts of Pt SAs (<0.1 at %) on exfoliated graphitic carbon nitride (CN) by a direct Pt-deposition approach from highly dilute chloroplatinic acid precursors.
View Article and Find Full Text PDFNature
December 2024
CatalYm, Munich, Germany.
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression commonly occurs. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Medicine (F.N.), Université de Montréal, Québec, Canada; David Geffen School of Medicine at the University of California, Los Angeles (K.G., A.F.); Warren Alpert Medical School of Brown University (J.-S.C.), Providence, RI; Division of Neurology (A.H.), Department of Pediatrics, Sainte-Justine University Hospital Centre, Montréal; Brain and Development Research Axis (A.H., A.G.W.), Centre de Recherche Azrieli du CHU Sainte-Justine, Montréal; Department of Neuroscience (M.R.K., D.K.N.), Université de Montréal; Research Centre of the University of Montreal Hospital Center (CRCHUM) (M.R.K., D.K.N.); Division of Neurology (M.R.K., D.K.N.), University of Montreal Hospital Center (CHUM); Laboratoire d'Imagerie Optique en Neurodéveloppement (LIONlab) (A.G.), CHU Sainte-Justine Research Center, Montréal; Cerebrum (A.G.), Department of Psychology, Université de Montréal, Québec, Canada; Department of Neurological Surgery (N.S.), Northwestern University Feinberg School of Medicine, Chicago, IL; Neuroscience Advanced Clinical Imaging Service (NACIS) (J.Y.-M.Y.), Department of Neurosurgery, The Royal Children's Hospital; Department of Paediatrics (J.Y.-M.Y.), The University of Melbourne; Neuroscience Research (J.Y.-M.Y.), Murdoch Children's Research Institute, Melbourne, Australia; Hope for Hypothalamic Hamartomas Organization (L.S., E.W.); APHM (B.D., D.S.), Timone Hospital, Epileptology and Cerebral Rhythmology, Marseille, France; Jane and John Justin Institute for Mind Health (M.S.P.), Cook Children's Health Care System, Fort Worth, TX; Division of Neurosurgery (K.M., G.M.I.), Hospital for Sick Children; Neurosciences & Mental Health (K.M., G.M.I.), SickKids Research Institute, Toronto, Ontario, Canada; Center for Neuroscience Research (W.D.G.), and Department of Neurology (W.D.G.), Children's National Hospital, George Washington University School of Medicine, Washington, DC; Department of Neurosurgery (D.M.), Université de Sherbrooke, Quebec, Canada; Pediatric Neurology Division (J.F.K.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; and Department of Neurosurgery (A.F.), David Geffen School of Medicine at the University of California, Los Angeles; Division of Neurosurgery (A.G.W.), Department of Surgery, Sainte-Justine University Hospital Centre, Montréal; Division of Neurosurgery (A.G.W.), Department of Surgery, University of Montreal Hospital Center (CHUM), Montréal, Québec, Canada.
Background And Objectives: There is a paucity of data directly comparing the outcome of surgical techniques available for the treatment of hypothalamic hamartomas (HHs). This study aims to evaluate the safety and efficacy of commonly used surgical approaches in the treatment of HH-related epilepsy.
Methods: A systematic review and individual participant data (IPD) meta-analysis was conducted.
Nat Immunol
January 2025
Department of Neurology, Yale School of Medicine, New Haven, CT, USA.
Effective anti-tumor immunity is driven by cytotoxic CD8 T cells with specificity for tumor antigens. However, the factors that control successful tumor rejection are not well understood. Here we identify a subpopulation of CD8 T cells that are tumor-antigen-specific and can be identified by KIR expression but paradoxically impair anti-tumor immunity in patients with melanoma.
View Article and Find Full Text PDFNanomaterials (Basel)
November 2024
Université Paris-Saclay, CEA Saclay, CNRS, NIMBE, UMR 3685, LIONS, 91191 Gif-Sur-Yvette CEDEX, France.
This study compares the mobility behaviour, in a HO environment, of three different geometries of hybrid particle made of silica core functionalized by gold (nanoparticles or layer). It is known that the decomposition of HO on gold surfaces drives mobility; however, the link between mobility orientation and the organization of gold on silica surfaces is still questionable. While conventional wisdom posits that asymmetric designs are crucial for generating phoretic forces or localized bubble propulsion, recent research suggests that symmetrical particles may also exhibit motility.
View Article and Find Full Text PDFRadiology
November 2024
From the Département d'Imagerie, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94805 Villejuif, France (L.D., S.A., J.H., S. Morer, C.D., F. Bidault, C.B., S. Muller, N.L.); Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay (BioMAPS), Université Paris-Saclay, Inserm, Centre national de la recherche scientifique, Commissariat à l'Énergie Atomique, Villejuif, France (Y.B., L. Lawrance, O.G., S.A., F.W., F. Bidault, C.B., N.L.); OPtimisation Imagerie et Santé (OPIS), Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France (Y.B., H.T.); Departments of Medical Biology and Pathology (D.V., L. Lacroix, E.R.), Cancer Medicine (M.A., M.S., S. Moog, M.F.M., M.T., A.B.T., B.V., N.A., B.B., F.A., F. Barlesi), Hematology (J.B.M.), and Genetics (O.C.), Gustave Roussy, Villejuif, France; Departments of Imaging (M.K.) and Medical Oncology (A.I.), Institut Bergonié, Bordeaux, France; Département d'Innovation Thérapeutique et des Essais Précoce, Gustave Roussy, Villejuif, France (A.B., L.B., C.N., A. Geraud, M.S., F.B.D., C.S., A. Gazzah, A.H., Y.L., S.P., A.I.); Oncostat, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France (A.B.); Mathématiques et Informatique pour la Complexité et les Systèmes (MICS), CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France (P.H.C.); Université Paris-Saclay, Faculté de médecine, Le Kremlin Bicêtre, Paris, France (A.B., B.B., F.A., J.C.S., F. Barlesi, N.L.); Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (L.B.); Gustave Roussy, Villejuif, France (J.C.S.); and Guerbet Research, Villepinte, France (L. Lawrance).
Background Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023.
View Article and Find Full Text PDFJ Exp Med
December 2024
Section of Paediatric Infectious Disease, Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
Multisystem inflammatory syndrome in children (MIS-C) is a rare condition following SARS-CoV-2 infection associated with intestinal manifestations. Genetic predisposition, including inborn errors of the OAS-RNAseL pathway, has been reported. We sequenced 154 MIS-C patients and utilized a novel statistical framework of gene burden analysis, "burdenMC," which identified an enrichment for rare predicted-deleterious variants in BTNL8 (OR = 4.
View Article and Find Full Text PDFNat Genet
December 2024
Institute of Health Informatics, University College London, London, UK.
Neurol Neuroimmunol Neuroinflamm
January 2025
From the Departments of Pediatric Neurology (S.S., A.B., K.R.), and Pediatric Radiology (A.P., R.C.), Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany; Consultant Child Neurologist and Epileptologist at Neoclinic Children's Hospital (V.J.), Jaipur, India; Department of Pediatric Neurology (T.K.), Children's Hospital Datteln, University Witten/Herdecke; Faculty of Health (T.K.), Department of Psychology and Psychotherapy, Chair of Personality Psychology and Diagnosis, Witten/Herdecke University; Center for Paediatric and Adolescent Medicine (U.D.), University Medical Clinic, Mainz; University Children's Hospital Regensburg (KUNO) (T.G.), Hospital St. Hedwig of the Order of St. John, University of Regensburg; Department of Pediatric Neurology (A.N.), VAMED Klinik Geesthacht; Department of Pediatrics (A.N.), University Medical Center Hamburg-Eppendorf; Department of Pediatric Neurology (C.L.-N.), Mutterhaus der Borromäerinnen, Trier; Department of Pediatric Intensive Care (R.A.-H.), University Children's Hal Marburg; Department of Pediatric Neurology (M.F.-B.), Saarland University Medical Center, Homburg/Saar, Germany; Assistance Publique-Hôpitaux de Paris (K.D.), Paris-Saclay University Hospitals, Bicêtre Hospital, Pediatric Neurology Department, National Referral Center for Rare Inflammatory and Auto-immune Brain and Spinal Diseases, Paris Saclay University, France; Neuroimmunology Unit (T.A.), in Sant Joan de Déu Children's Hospital, Esplugues de Llobregat, Barcelona; Neuroimmunology Program (T.A., G.O.-C.), Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona; Neurology Unit (G.O.-C.), Hospital Parc Taulí de Sabadell, Sabadell, Barcelona, Spain; Neuroimmunology Laboratory (S.K.), Amrita Institute of Medical Sciences, School of Medicine, Amrita University, Kochi, India; Department of Pediatrics (A.K.); Center for Rare Diseases (A.K.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Department of Pediatric Neurology (H.M.); Pediatric Neurology Institute (A.F.-V.), Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center; Sackler Faculty of Medicine, Tel Aviv University; Institute of Pediatric Neurology (E.G.-C.), Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel; University Children's Hospital Oldenburg (H.L.), Department of Neuropediatrics, Oldenburg; Neuropediatric Unit (A.H., R.W.), Karolinska University Hospital and Karolinska Institute Stockholm, Sweden; and Institute of Clinical Chemistry (J.D., F.L.), Neuroimmunology Unit and Department of Neurology, University Medical Center Schleswig-Holstein Campus, Kiel, Germany.
N Engl J Med
November 2024
From the Department of Neurosurgery, Stony Brook Medicine, Stony Brook, NY (D.F.); the Department of Neurosurgery, Swedish Cherry Hill Hospital, Seattle (S.J.M.); the Department of Neurosurgery, Baptist Memorial Hospital, Jacksonville, FL (R.H.); the Department of Neurosurgery, Swedish Medical Center, Englewood, CO (B.A.); the Department of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University Medicine, Morgantown (S.B.); the Department of Radiology, Rhode Island Hospital, Providence (R.A.M.); the Department of Neurosurgery, Santa Barbara Cottage Hospital, Santa Barbara, CA (A.Z.); the Department of Neurosurgery, Thomas Jefferson Hospital, Philadelphia (S.T.); the Department of Radiology, Centre Hospitalier Universitaire (CHU) Côte de Nacre, Caen (C.B.), the Department of Radiology, CHU Hôpital Bicêtre, Kremlin-Bicêtre (L.S.), and the Department of Radiology, CHU Hôpital Maison Blanche, Reims (L.P.) - all in France; the Department of Neurosurgery, Atlantic Center for Research, Morristown, NJ (R.B.); the Department of Radiology, Massachusetts General Hospital, Boston (J.A.H.); and the Cerebrovascular Program, Vanderbilt University Medical Center, Nashville (M.F.), and the Department of Neurosurgery, University of Tennessee Health Science Center, and the Semmes Murphey Clinic, Memphis (A.S.A.) - all in Tennessee.
Background: Patients receiving standard treatment for chronic subdural hematoma have a high risk of treatment failure. The effect of adjunctive middle meningeal artery embolization on the risk of treatment failure in this population remains unknown.
Methods: We randomly assigned patients with symptomatic chronic subdural hematoma to undergo middle meningeal artery embolization as an adjunct to standard treatment (embolization group) or to receive standard treatment alone (control group).
Background: The EXCELLENT registry aimed to evaluate the effectiveness of the EMBOTRAP Revascularization Device in an all-comer population in a real-world setting, with a focus on the composition of retrieved clots.
Methods: EXCELLENT is a prospective, global registry of patients with acute ischemic stroke treated with EMBOTRAP as the first-line mechanical thrombectomy device conducted at 34 sites (25 sites contributing clot) from September 2018 to March 2021, utilizing core imaging and central histology laboratories blinded to clinical data, independent 90-day modified Rankin Scale assessment and Clinical Events Committee.
Results: After screening 3799 patients, a total of 997 subjects (mean age, 70.
N Engl J Med
December 2024
From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) - both in London; Brigham and Women's Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) - both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo-Universitaire de Bicêtre, Assistance Publique-Hôpitaux de Paris, University Paris-Saclay, Le Kremlin-Bicêtre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.).
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) targeting the gene encoding transthyretin ().
Methods: In this phase 1, open-label trial, we administered a single intravenous infusion of nex-z to patients with ATTR-CM.
Nat Rev Drug Discov
January 2025
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
In recent years, a small number of people with rare diseases caused by unique genetic variants have been treated with therapies developed specifically for them. This pioneering field of genetic N-of-1 therapies is evolving rapidly, giving hope for the individualized treatment of people living with very rare diseases. In this Review, we outline the concept of N-of-1 individualized therapies, focusing on genetic therapies, and illustrate advances and challenges in the field using cases for which therapies have been successfully developed.
View Article and Find Full Text PDFNat Commun
October 2024
Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Neurology
November 2024
From the Reference Center for Neuromuscular Diseases and ALS (E.F., E.D., S.A.), La Timone University Hospital, Marseille; UMR CNRS 7339 (E.F., C.P.M., M.G., D.B.), Center for Magnetic Resonance in Biology and Medicine, Marseille; CNRS, LIS (M.A.H., M.-E.B.), UMR 7286, Medicine Faculty (E.D.), and Inserm, GMGF (S.A.), Aix-Marseille University, France.
Sci Rep
October 2024
European Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
MYCN-amplified RB1 wild-type (MYCNRB1) retinoblastoma is a rare and aggressive subtype, often resistant to standard therapies. Identifying unique MRI features is crucial for diagnosing this subtype, as biopsy is not recommended. This study aimed to differentiate MYCNRB1 from the most prevalent RB1 retinoblastoma using pretreatment MRI and radiomics.
View Article and Find Full Text PDFEuropace
October 2024
Department of Cardiology, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France.